
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
The basis for examining the genetic make-up (genome-wide gene expression levels) of cells is single-cell RNA sequencing, also known as single-cell transcriptomics.
In recent years, spatial transcriptomic technologies have made it possible to profile gene expression levels with spatial location information of cell "neighborhoods," showing precise locations and movements of cells within tissue.Additional "omics" have provided detail on a variety of molecular features.
Simulators have improved and grown in power, but they still have many drawbacks. Few are capable of simulating real data to produce accurate single-cell RNA sequencing data from continuous cell trajectories, and most are unable to model multi-omics and spatial transcriptomics data.
To bridge the gap between benchmarking requirements for academics and the constraints of available tools, we developed the scDesign3, which we feel is the most realistic and functional simulator to date.
The ability to specifically customize medications and treatments to a particular gene location on particular types of cells has been made possible in large part by single-cell sequencing. In addition to being more complete, sequencing technology is more sensitive and requires less sample material than other methods.
Now that there is a means to discover these targets while minimizing potential harm to nearby cells, it is possible for researchers to delve deeper into the biology of various systems than was previously possible.
Researchers can now identify specific genetic alterations in different subtypes of cancer that may explain why some cancers are more resistant to specific treatments by combining single-cell DNA (scDNA-seq) or RNA (scRNA-seq) sequencing data with other computational tools.
The Global Single-Cell Sequencing Tools market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
In an announcement made during the J.P. Morgan Healthcare Conference, Illumina, Inc. and Bio-Rad Laboratories, Inc. introduced the Illumina® Bio-Rad® Single-Cell Sequencing Solution.
The comprehensive solution is the first next-generation sequencing (NGS) process for single-cell analysis, enabling researchers to look into the coordinated role of individual cells in tissue function, disease development, and therapy response.
This makes it possible to examine individual cells' gene expression in great detail in order to comprehend how they work in intricate tissues. The system provides thousands of individual cell sequencing at high throughput, which is often a difficult, expensive, and time-consuming process.
The sectors that stand to gain the most from this new service are those studying human development and disease, where single-cell sequencing has a wide range of applications.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |